Ann: Mayne Pharma appoints new CFO, page-10

Ddd is very critical of the way the business has been handled and makes some good points,however to be selling out at this point in time could turn out very badly psychologically,especially if it’s goes in an uptrend with approvals expected soon . If holders would like to risk trading and getting in lower that’s their call .At the end of the day my suggestions is that for people who are sick and tired of continuous disappointment at least wait for Nuvaring and jump out after the suspected bounce.Loyal supporters can then stay on wait for E4 and hope for big rewards with improved profitability and revenue which is what I’ll be doing ,right or wrong we shall see.u